Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1988 Sep;82(3):803–807. doi: 10.1172/JCI113682

Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I.

Y Yui 1, T Aoyama 1, H Morishita 1, M Takahashi 1, Y Takatsu 1, C Kawai 1
PMCID: PMC303586  PMID: 3047170

Abstract

Serum PGI2 stabilizing factor (PSF) was purified from human serum to a single protein with a molecular weight of 28,000 D by SDS-PAGE. Analyses of NH2-terminal sequence (32 residues), COOH-terminal sequence (3 residues) and the composition of amino acids disclosed its homology with human apolipoprotein A-I (Apo A-I), a major apolipoprotein of HDL. Apolipoprotein A-II, C-I, C-II, C-III, D and E, as well as LDL, and VLDL did not possess this activity. The alpha-helix structure of Apo A-I is necessary for the binding of PGI2. HDL and nascent HDL reconstituted from Apo A-I and phospholipid significantly prolonged the half-life of PGI2. PGI2 stabilization by HDL and Apo A-I may be an important protective action against the accumulation of platelet thrombi at sites of vascular damage. The beneficial effect of HDL in the prevention of coronary artery disease may be partly due to this action.

Full text

PDF
803

Images in this article

805Image
on p.805
806Image
on p.806
806Image
on p.806
806Image
on p.806

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Edelstein C., Lim C. T., Scanu A. M. On the subunit structure of the protein of human serum high density lipoprotein. I. A study of its major polypeptide component (Sephadex, fraction 3). J Biol Chem. 1972 Sep 25;247(18):5842–5849. [PubMed] [Google Scholar]
  2. Eisenberg S. High density lipoprotein metabolism. J Lipid Res. 1984 Oct;25(10):1017–1058. [PubMed] [Google Scholar]
  3. Fielding C. J., Shore V. G., Fielding P. E. A protein cofactor of lecithin:cholesterol acyltransferase. Biochem Biophys Res Commun. 1972 Feb 25;46(4):1493–1498. doi: 10.1016/0006-291x(72)90776-0. [DOI] [PubMed] [Google Scholar]
  4. Gordon D. J., Knoke J., Probstfield J. L., Superko R., Tyroler H. A. High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. Circulation. 1986 Dec;74(6):1217–1225. doi: 10.1161/01.cir.74.6.1217. [DOI] [PubMed] [Google Scholar]
  5. Green M. S., Heiss G., Rifkind B. M., Cooper G. R., Williams O. D., Tyroler H. A. The ratio of plasma high-density lipoprotein cholesterol to total and low-density lipoprotein cholesterol: age-related changes and race and sex differences in selected North American populations. The Lipid Research Clinics Program Prevalence Study. Circulation. 1985 Jul;72(1):93–104. doi: 10.1161/01.cir.72.1.93. [DOI] [PubMed] [Google Scholar]
  6. HAVEL R. J., EDER H. A., BRAGDON J. H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955 Sep;34(9):1345–1353. doi: 10.1172/JCI103182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hajjar D. P., Weksler B. B., Falcone D. J., Hefton J. M., Tack-Goldman K., Minick C. R. Prostacyclin modulates cholesteryl ester hydrolytic activity by its effect on cyclic adenosine monophosphate in rabbit aortic smooth muscle cells. J Clin Invest. 1982 Sep;70(3):479–488. doi: 10.1172/JCI110639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jackson R. L., Morrisett J. D., Gotto A. M., Jr Lipoprotein structure and metabolism. Physiol Rev. 1976 Apr;56(2):259–316. doi: 10.1152/physrev.1976.56.2.259. [DOI] [PubMed] [Google Scholar]
  9. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  10. Maciejko J. J., Holmes D. R., Kottke B. A., Zinsmeister A. R., Dinh D. M., Mao S. J. Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease. N Engl J Med. 1983 Aug 18;309(7):385–389. doi: 10.1056/NEJM198308183090701. [DOI] [PubMed] [Google Scholar]
  11. Matz C. E., Jonas A. Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. J Biol Chem. 1982 Apr 25;257(8):4535–4540. [PubMed] [Google Scholar]
  12. Miller G. J., Miller N. E. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975 Jan 4;1(7897):16–19. doi: 10.1016/s0140-6736(75)92376-4. [DOI] [PubMed] [Google Scholar]
  13. Norum R. A., Lakier J. B., Goldstein S., Angel A., Goldberg R. B., Block W. D., Noffze D. K., Dolphin P. J., Edelglass J., Bogorad D. D. Familial deficiency of apolipoproteins A-I and C-III and precocious coronary-artery disease. N Engl J Med. 1982 Jun 24;306(25):1513–1519. doi: 10.1056/NEJM198206243062503. [DOI] [PubMed] [Google Scholar]
  14. Orchard M. A., Robinson C. Stability of prostacyclin in human plasma and whole blood: studies on the protective effect of albumin. Thromb Haemost. 1981 Oct;46(3):645–647. [PubMed] [Google Scholar]
  15. Pifer D. D., Cagen L. M., Chesney C. M. Stability of prostaglandin I2 in human blood. Prostaglandins. 1981 Feb;21(2):165–175. doi: 10.1016/0090-6980(81)90135-0. [DOI] [PubMed] [Google Scholar]
  16. Scanu A. Forms of human serum high density lipoprotein protein. J Lipid Res. 1966 Mar;7(2):295–306. [PubMed] [Google Scholar]
  17. Shelburne F. A., Quarfordt S. H. The interaction of heparin with an apoprotein of human very low density lipoprotein. J Clin Invest. 1977 Oct;60(4):944–950. doi: 10.1172/JCI108849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Shore V. G., Shore B. Heterogeneity of human plasma very low density lipoproteins. Separation of species differing in protein components. Biochemistry. 1973 Jan 30;12(3):502–507. doi: 10.1021/bi00727a022. [DOI] [PubMed] [Google Scholar]
  19. Shoulders C. C., Kornblihtt A. R., Munro B. S., Baralle F. E. Gene structure of human apolipoprotein A1. Nucleic Acids Res. 1983 May 11;11(9):2827–2837. doi: 10.1093/nar/11.9.2827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Stein R. W., Papp A. C., Weiner W. J., Wu K. K. Reduction of serum prostacyclin stability in ischemic stroke. Stroke. 1985 Jan-Feb;16(1):16–18. doi: 10.1161/01.str.16.1.16. [DOI] [PubMed] [Google Scholar]
  21. Swaney J. B. Reconstitution of apolipoprotein A-I from human high density lipoprotein with bovine brain sphingomyelin. J Biol Chem. 1983 Jan 25;258(2):1254–1259. [PubMed] [Google Scholar]
  22. Vane J. R. Prostaglandins and the cardiovascular system. Br Heart J. 1983 May;49(5):405–409. doi: 10.1136/hrt.49.5.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Wu K. K., Hall E. R., Rossi E. C., Papp A. C. Serum prostacyclin binding defects in thrombotic thrombocytopenic purpura. J Clin Invest. 1985 Jan;75(1):168–174. doi: 10.1172/JCI111670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Wynalda M. A., Fitzpatrick F. A. Albumins stabilize prostaglandin I2. Prostaglandins. 1980 Nov;20(5):853–861. doi: 10.1016/0090-6980(80)90138-0. [DOI] [PubMed] [Google Scholar]
  25. Wynalda M. A., Lincoln F. H., Fitzpatrick F. A. High-performance liquid chromatographic assay for prostacyclin. J Chromatogr. 1979 Sep 1;176(3):413–417. doi: 10.1016/s0021-9673(00)89460-1. [DOI] [PubMed] [Google Scholar]
  26. Yui Y., Aoyama T., Murohara R., Takatsu Y., Susawa T., Yui N., Hattori R., Kawai C. Serum PGI2-regulating factors in acute myocardial infarction. Jpn Circ J. 1987 Apr;51(4):462–464. doi: 10.1253/jcj.51.462. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES